A Cohort Study of Correlation Between Mast Cells and Prognosis in Patients With Acute Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

By including patients with acute myocardial infarction, mast cell markers were analyzed and the relationship between mast cells and patients with acute myocardial infarction was analyzed

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of the Diagnostic Performance of the Detection System and Establishment of an Intelligent and Rapid Triage Model

NCT06864676

Coronary Heart Disease (CHD)

NOT_YET_RECRUITING

Initial CT Perfusion-Guided Strategy for Suspected NSTEMI

NCT06689267

Non-ST Elevation Myocardial Infarction

RECRUITING NA

Myeloid-Related Protein in Evaluation of Acute Chest Pain in the Emergency Departement

NCT00657436

Myocardial Ischemia Acute Coronary Syndrome Myocardial Infarction +2 more

COMPLETED

Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome

NCT01698021

Acute Coronary Syndrome Myocardial Infarction Unstable Angina

UNKNOWN

Relationship Between Level of GPCR Autoantibodies and Cardiac Structure & Funtions Based on UCG and CMR

NCT05368584

STEMI

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Percutaneous coronary intervention (PCI) is the best way to improve the prognosis of patients with acute ST-segment elevation myocardial infarction (STEMI). However, ischemia reperfusion injury, inappropriate ventricular remodeling, and myocardial fibrosis may still be present in STEMI after PCI, which may be related to the inflammatory response in STEMI. Mast cells (MC), their degranulation products and induction of a series of inflammatory cytokines play an important role in the inflammatory response. The purpose of this study was to evaluate the relationship between mast cell markers (trypsin, chymotrypsin) levels and prognosis after direct PCI in STEMI patients. We prospectively and continuously included STEMI patients undergoing standard therapy after direct PCI. Clinical data and blood samples were collected and followed up for 1 year to analyze mast cell markers and myocardial infarction size. As well as differences in echocardiography, markers of two-dimensional speck tracking techniques, inflammatory factors and major adverse cardiovascular events, to explore the relationship between mast cells and their products and ventricular remodeling and ischemia-reperfusion injury in STEMI patients, and to provide new ideas for treatment and new basis for optimization of STEMI treatment strategies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammation Acute ST Segment Elevation Myocardial Infarction Prognosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

STEMI

A total of 300 STEMI patients admitted to the Department of Cardiology, Peking University Third Hospital from April 1, 2023 to March 31, 2024 were enrolled.

Tryptase

Intervention Type DIAGNOSTIC_TEST

Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tryptase

Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age above 18 years old, regardless of gender;
* 2\) Meet STEMI diagnostic criteria (diagnostic criteria: ischemic chest pain lasting ≥30min; ST segment elevation of more than two adjacent leads or new left bundle branch block in ECG; With or without elevated myocardial markers) and receiving standard care for STEMI.
* 3\) Agree to and cooperate with the study

Exclusion Criteria

* 1\) The patient is taking or planning to take long-term oral or intravenous glucocorticoids (inhaled and topical hormones are allowed);
* 2\) Allergic diseases, autoimmune diseases or malignant tumors.
* 3\) Patients with metal implants or claustrophobia are not allowed to undergo an MRI examination;
* 4\) Pregnancy or lactation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No